Search Medical Condition
Please enter condition
Please choose location from dropdown

Burlington, Massachusetts Clinical Trials

A listing of Burlington, Massachusetts clinical trials actively recruiting patient volunteers.

RESULTS

Found (202) clinical trials

Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads

The QP ExCELs study is designed to confirm safety and efficacy of the BIOTRONIK Sentus OTW QP left ventricular leads to satisfy FDA requirements for regulatory approval of the leads in the US. The Sentus OTW QP leads received FDA approval on May 4, 2017. Long-term safety of the BIOTRONIK ...

Phase N/A

0.38 miles

Learn More »

This research study will look at how effective niraparib (a PARP inhibitor) is compared to placebo (a pill with no medicine in it, like a sugar pill) in maintenance therapy for women who have ovarian, fallopian tube or peritoneal cancer, and have responded (complete or partial response) to front-line platinum-based ...

Phase

0.38 miles

Learn More »

The purpose of this study is to evaluate the overall response rate (ORR) of INCB054828 as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.

Phase

0.38 miles

Learn More »

STAMCAR: A Prospective EC-IC Bypass Registry

The registry is a multi-center international prospective registry. The patients will be prospectively followed for 24 months. Enrollment into the registry will take place over 3 years. The primary objective is to collect prospective data on cerebral revascularization via superficial temporal artery (STA) to middle cerebral artery (MCA) for symptomatic ...

Phase N/A

0.61 miles

Learn More »

CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD

The objective of this study is to evaluate the safety and effectiveness of the MobiusHD System in a prospective, randomized, double-blind, sham-controlled multi-center pivotal study. Patients with resistant hypertension who remain uncontrolled despite pharmacologic treatment with maximum tolerated, guideline-directed anti-hypertensive pharmacologic therapy will be evaluated.

Phase N/A

0.61 miles

Learn More »

Hybrid L24 New Enrollment Post Approval Study

This study evaluates the long term safety and effectiveness of the Nucleus Hybrid L24 Implant in a group of newly implanted adults.

Phase N/A

0.61 miles

Learn More »

Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry

This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research ...

Phase N/A

0.61 miles

Learn More »

SLIP II Registry: Spinal Laminectomy Versus Instrumented Pedicle Screw Fusion

Aim: To conduct a randomized control trial comparing patient outcomes and satisfaction with or without expert panel review before making a final decision about surgery for grade I degenerative lumbar spondylolisthesis. A prospective, multi-center registry aimed at addressing important issues pertaining to outcomes from treatment for degenerative spondylolisthesis and spinal ...

Phase N/A

0.61 miles

Learn More »

P-15L Bone Graft in Transforaminal Lumbar Interbody Fusion With Instrumentation

The aim of this trial is to evaluate if P-15L bone graft (investigational device) is not inferior in effectiveness and safety to local autologous bone (and allograft where necessary) as an extender (control device) when applied in instrumented transforaminal lumbar interbody fusion (TLIF) in subjects with degenerative disc disease (DDD). ...

Phase N/A

0.61 miles

Learn More »

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole Based on Prior Endocrine Therapy in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatments

Phase

1.42 miles

Learn More »